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Background: Diagnosis within RASopathies still represents a challenge. Nevertheless, many efforts have been made by
clinicians to identify specific clinical features which might help in differentiating one disorder from another. Here, we
describe a child initially diagnosed with Neurofibromatosis-Noonan syndrome. The follow-up of the proband, the
clinical evaluation of his father together with a gene-by-gene testing approach led us to the proper diagnosis.
Case presentation: We report a 8-year-old male with multiple café-au-lait macules, several lentigines and dysmorphic
features that suggest Noonan syndrome initially diagnosed with Neurofibromatosis-Noonan syndrome. However, after
a few years of clinical and ophthalmological follow-up, the absence of typical features of Neurofibromatosis type 1 and
the lack of NF1 mutation led us to reconsider the original diagnosis. A new examination of the patient and his similarly
affected father, who was initially referred as healthy, led us to suspect LEOPARD syndrome, The diagnosis was then
confirmed by the occurrence in both patients of a heterozygous mutation c.1403 C > T, p.(Thr468Met), of PTPN11.
Subsequently, the proband was also found to have type-1 Arnold-Chiari malformation in association with syringomyelia.
Conclusion: Our experience suggests that differential clinical diagnosis among RASopathies remains ambiguous and
raises doubts on the current diagnostic clinical criteria. In some cases, genetic tests represent the only conclusive proof
for a correct diagnosis and, consequently, for establishing individual prognosis and providing adequate follow-up. Thus,
molecular testing represents an essential tool in differential diagnosis of RASophaties. This view is further strengthened
by the increasing accessibility of new sequencing techniques.
Finally, to our knowledge, the described case represents the third report of the occurrence of Arnold Chiari
malformation and the second description of syringomyelia with LEOPARD syndrome.
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Noonan syndrome (NS, OMIM 163950), Neurofibroma-
tosis type 1 (NF1, OMIM 162200), LEOPARD syndrome
(LS, OMIM 151100), and Neurofibromatosis type 1-like
syndrome (NFLS, OMIM 611431) belong to the group
known as RASopathies [1]. They are characterized by over-
lapping phenotypic features; each one also comprises key
features that can help to differentiate one from another. NS
is relatively common; it affects approximately 1/1000 to 1/
2500 newborns. NS is characterized by postnatal reduced
growth, distinctive facial dysmorphisms, cardiac defects,* Correspondence: silverio.perrotta@unina2.it
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unless otherwise stated.and variable cognitive impairment in association with
other features, including ectodermal and skeletal defects,
cryptorchidism, lymphatic dysplasia, bleeding tendency,
and increased risk of developing malignancies during
childhood [2-4]. Diagnoses are made by clinical examin-
ation according to a comprehensive scoring system [5].
NS is characterized by extreme clinical and genetic vari-
ability [6].
Clinical diagnosis of NF1 is based on the presence of
two or more of the following signs: six or more café-au-
lait macules (CALMs); two or more neurofibromas of
any type or one plexiform neurofibroma; axillary or in-
guinal freckling; optic glioma; two or more Lisch nodules
of the iris; a distinctive osseous lesion; and/or a first-
degree relative diagnosed with NF1 according to the pre-
ceding criteria. Some of these features, such as spots andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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birth or during the first years of life [7]. On the other hand,
Lisch nodules and cutaneous neurofibromas tend to be-
come evident after 6 years of age [8]. Neurofibromatosis-
Noonan syndrome (NFNS) represents a specific entity in
which features of both NS and NF1 can be recognized [9].
The acronym LEOPARD stands for the cardinal features
of LS: lentigines, electrocardiographic (ECG) conduction
abnormalities, ocular hypertelorism, pulmonary stenosis,
abnormal genitalia, retardation of growth, and sensori-
neural deafness [10]. LS patients show a phenotype that
strongly overlaps with NS, although they are characterized
by a typical dispersed pattern of multiple lentigines and
CALMs, which are less frequently observed in NS [11]. A
diagnosis of LS is made on the observation of key features
such as lentigines, hearing loss and hypertrophic cardio-
myopathy (HCM) [5]. The same as for NF1, these clinical
signs of LS appear to be age related. Thus, NF1, NS, and
LS phenotypes may be indistinguishable in young children
and infants.
NFLS is a recently identified RASopathy characte-
rized by a mild NF1 phenotype with pigmentary changes,
macrocephaly, learning difficulties, and a tendency to de-
velop lipomas in adulthood. Lisch nodules and neurofibro-
mas are typically absent [12].
RASopathies always result from germline mutations of
genes that encode protein components of the Ras/MAPK
(mitogen-activated protein kinase) pathway [13]. Muta-
tions in NF1 are detected in approximately 95% of pa-
tients fulfilling the NIH clinical criteria [14]. NS can be
caused by mutations in several genes, including PTPN11,
KRAS, SOS1, RAF1, NRAS, BRAF, SHOC2, CBL and RIT1;
PTPN11 changes account for roughly 50% of cases [6,15].
PTPN11, BRAF, and RAF1 mutations are also mutated in
LS and are responsible for approximately 95% of cases,
with mutations in PTPN11 alone occurring in about 85%
of cases [16]. De Luca et al. provided strong evidence of a
major role for NF1 mutations in NFNS [9], while SPRED1
mutations have been identified in patients with NFLS [12].
Herein, we describe a child who initially fulfilled the
diagnostic criteria for NF1, but who later did not develop
typical features of NF1, such as Lisch nodules and neuro-
fibromas. After negative results for NF1 and SPRED1 mu-
tations, clinical examination of the patient and his family
history led us to suspect LS, which was subsequently con-
firmed by PTPN11 testing. Intriguingly, this led us to a
diagnosis of LS also in the proband’s father.
Case presentation
The proband was the first male child of non-consanguineous
healthy parents. He was spontaneously delivered after an
uncomplicated pregnancy that was the result of in-vitro
fertilization. Birth weight was 3.7 Kg (50th centile), and
length was 50 cm (50th centile). At 8 years of age, he wasreferred to our center because of multiple CALMs
(six, ≥5 mm). Examination also revealed several light-
brown lentigines on his face, neck, and thorax. Dys-
morphic features included hypertelorism; downslanting
palpebral fissures; epicanthus; coarse facial features; and
large, thick, low-set ears. Low posterior hairline, blond
curly hair, pterygium colli (Figure 1A), cubitus valgus,
chest deformity (Figure 1B), and umbilical herniation were
also noted. The boy weighed 25 kg (50th centile), with a
height of 126 cm (50th centile) and a cephalic perimeter
of 55 cm (95th centile). No genital or hearing anomalies
were detected. Based on these features, a clinical diagnosis
of NFNS was suspected and the child underwent a multi-
disciplinary follow-up, as advised for NF1 [17], including
periodic visual assessment [18].
A cranial MRI was performed because of headache; no
unidentified bright objects (UBOs) were detected. Lisch
nodules and neurofibromas were absent. ECG revealed no
abnormalities at the age of 9 years. Because mutations in
NF1 are known to be the major molecular event under-
lying NFNS, molecular genetic analysis of NF1 was per-
formed. However, no NF1 mutations were found. Because
of the lack of typical NF1 features (i.e., Lisch nodules and
neurofibromas) and elements that suggested a particular
RASopathy, a molecular analysis of SPRED1 was launched
when he was 11 years of age. No mutations were detected.
These negative molecular results led us to reevaluate our
initial clinical diagnosis. Thus, we asked to review the
child along with both of his parents.
The proband’s father, who was aged 50 years, came to
us first. He had always been referred as healthy, but a
history of benign arrhythmia, as well as post-natal onset
of growth retardation and peptic ulcer emerged from an
in-depth clinical anamnesis. The father had dysmorphic
features. Obvious hypertelorism; ptosis and coarse facial
features; large, thick ears with creased lobes; low poster-
ior hairline; chest deformity; multiple sparse, dark, small
spots and common nevi; a few CALMs; and a large mac-
ule on the leg (Figure 2) were detected. No genital prob-
lems were present. His height was 166 cm (5th centile),
and his head circumference was 60 cm (>95th centile).
His father and one of his brothers were reported to
share similar facial dysmorphisms without other referred
medical problems, such as deafness or cardiac problems.
The proband’s uncle had also undergone surgery because
of unilateral cryptorchidism.
Upon examination at the age of 12 years, the proband’s
CALMs, dysmorphic features (Figure 1C, D) and macro-
cephaly were confirmed and stable. However, the lentigi-
nes had acquired a pattern of distribution more suggestive
of LS and their color was darker than when previously ob-
served (Figure 1D–F). Thus, we began to suspect LS.
An echocardiography revealed mild dilatation of the
ascending aorta and hypertrophic cardiomyopathy in the
Figure 1 Photographs of the proband at 8 (A, B) and 12 (C-F)
years of age. (A) At the age of 8 the proband patient had blue eyes,
epicanthus, down-slanting palpebral fissures, hypertelorism, coarse
facial features, facial lentigines, and curly blond hair. (B) Pterigium colli,
pectus excavatum, hypertelorism, lentigines, and a large CALM were
noted. At the age of 12 years, the proband showed (C) persistence of
the facial dysmorphism previously noted; (D) low-set and posteriorly
rotated thick, large ears with lobe creases; and (E, F) low posterior hair
line and CALMs and an increased number, more widespread pattern of
distribution, and deeper color intensity of lentigines.
Figure 2 Photographs of the proband’s father at 50 years of
age. The proband’s father had (A) coarse facial features,
hypertelorism, and ptosis; (B) large, thick, low-set ears with lobe
creases; (C) pectus excavatum and hypertelia; (D) low posterior hair
line; (D, E) lentigines; and (F) a large CALM on the left leg (F).
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with an ejection fraction (EF) of 70% and mitral valve
prolapse in the proband. Mixed mild deafness was
demonstrated in the father, but no auditory problems
were detected in the proband. Molecular genetic tes-
ting of PTPN11 was performed, and a previously de-
scribed pathological heterozygous mutation c.1403C > T, p.(Thr468Met), was detected in both the pro-
band and his father. The proband recently underwent
an MRI scan of the spine because of thermal and pain
hypoestesia of the upper left arm. A syrinx in the
cervical spine, extending into the thoracic spine, and
a type-1 Arnold-Chiari malformation were detected
(Figure 3).
All patients gave informed written consent on ente-
ring the study, which had been approved by the Second
University of Naples, Ethics Committee, in accordance
with the Declaration of Helsinki.
Figure 3 Magnetic resonance image of the proband. Sagittal SE T1-weighted cervical MRI (A, B) shows cerebrospinal fluid (CSF)-filled cavity
(*) in the middle of the central cervical and thoracic spinal cord (SC), with multiple caudal septations. These non-neoplastic septated (white arrows)
paracentral fluid containing cavitations are referred to as hydrosyringomyelia. Sagittal SE T1-weighted brain MRI (C) with the basion-opisthion line
(BOL) shown in white. Note crowded foramen magnum and the low-lying pointed tonsil with distance from BOL >5 mm (black arrow), consistent with
Chiari malformation 1. Axial MERGE T2*-weighted cervical MRI (D) shows a well-demarcated CSF cavity (*) in the middle central and left paracentral SC.
VB, vertebral body; NF, neural foramina; SP, spinous process.
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A new class of genetic disorders, the “RASopathies”, has re-
cently emerged. To date, this nosologic group comprises
NS, LS, Hereditary gingival fibromatosis type 1, Capillary
Malformation-AV malformation syndrome, NF1, NFLS,
Costello syndrome, Cardio-facio-cutaneous syndrome
(CFC), and Autoimmune Lymphoproliferative syndrome
(ALPS) [13]. Collectively, these conditions represent rela-
tively common monogenic disorders. Although each one
exhibits typical phenotypic features, they share many
clinical signs, including craniofacial anomalies; congeni-
tal heart defects; short stature; varying degrees of neuro-
cognitive impairment; cutaneous and musculoskeletal
abnormalities and predisposition to malignancies. Thus,
differential diagnosis can represent a clinical dilemma,
particularly among NF1, NS, LS, and NFLS.
Several case reports of patients with borderline pheno-
types that illustrate this clinical overlap have been pub-
lished. For example, Wu et al. [19] reported a de novo
NF1 mutation in a woman with a prior diagnosis of LS.
Moreover, Carcavilla et al. [20] reported three children
who filled NF1 clinical criteria but were diagnosed with
LS and carried the PTPN11 mutation p.(Thr468Met), the
same mutation detected in our patients. Carcavilla et al.
[20] suggested that a distinguishing feature for LS might
be the diffuse pattern of lentigines, even if they seem to
appear later in life than CALMs; this is in accord with ourpersonal observations. The patients described in this pre-
vious report had cardiomyopathy but lacked other features
typical of LS, such as deafness or genital abnormalities.
Our patients similarly lacked these types of clinical signs.
We noted a strong dysmorphic feature overlap between
our young patient and the one described by Nystrom et al.
[21]. The child described by Nystrom et al. [21], who had a
clinical diagnosis of NS because of pulmonic stenosis and
NS facial dysmorphisms, was discovered to carry the BRAF
mutation p.(Lys499Glu). The authors proposed a gene-
based classification of RASopathies and suggested that
NS and CFC are allelic disorders of BRAF. A BRAF ana-
lysis was performed for our proband, and no mutation
was found. Taking into account the dysmorphic overlap
between our proband (clinically diagnosed with LS and
carrying a PTNP11 mutation) and Nystrom’s patient (di-
agnosed with NS due to BRAF mutation), we enforce
the opinion that a straightforward genotype–phenotype
relationship is not always present among RASopathies.
In the last 10 years, we did experience with other simi-
lar cases. A 3-year-old boy was addressed to us because
of CALMs (n° 5) in suspicion of NF1. He showed mild
Noonan like dymorphisms, pulmonary stenosis and was
a sporadic case. We performed PTPN11 analysis as first
genetic test that led us to NS diagnosis. The other patient
was a 18 months-old female with few CALMs and lentigi-
nes who initially received diagnosis of NF1. Intriguingly,
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she received diagnosis of HCM and developmental delay.
Sparse and slow growing hair and Noonan dysmorphisms
were also present. The PTPN11 analysis detected a muta-
tion compatible with LS. All these observations point to the
PTPN11 gene, instead of NF1, as the first gene to be ruled
out if the differential diagnosis of NFNS/NFLS/LS. On the
contrary, a male with CALMs, joint laxity, frontal bossing,
macrocephaly, pulmonary stenosis and no lentigines at the
age of 5, suspected to be affected by NS, received diagnosis
of NF1 after the molecular analysis (firstly performed be-
cause of the number of CALMs = 6).
We also report diagnosis of NFLS in 4 patients (3 familiar
cases, and one sporadic), and their affected relatives, who
previously received diagnosis of NF1. Due to the lacking of
NF1 typical stigmata, NF1 analysis was performed but any
mutation was detected. Nevertheless the clinical diagnosis
of NF1 was confirmed. After a long follow-up (4–10 years),
and after the detection of SPRED1 mutations as the genetic
cause of NFLS, the diagnosis was changed.
The recent description of NFLS produced new questions,
particularly about the limits of the diagnostic criteria for
NF1 and the clinical homogeneity of this condition. The
current clinical diagnostic criteria for RASopathies seem to
be inadequate, especially when the patient is observed dur-
ing childhood, when some age-dependent manifestations
are not yet present. Patients who are young and who appear
to lack a familial history of RASopathy, need to be clinically
reviewed and other specific consultations (e.g., ophthal-
mological, dermatological, cardiological and audiometric)
should be performed in order to reach a correct diagnosis.
Unfortunately, these additional evaluations may be associ-
ated with burdensome health care costs. Muram et al. [22]
reported a cost saving approach by SPRED1 analysis in pa-
tients with a probable NF1 diagnosis. The genetic testing
was cost saving between the ages of 9 and 15 years in indi-
viduals with multiple CALMs with or without freckling
compared to the no-testing approach with routine follow-
up. Furthermore, Lepri et al. [23] reported a next gene-
ration analysis (integrated by Sanger sequencing of the
remaining not-covered regions) resulting 6 time less ex-
pensive than protocols entirely based on Sanger sequen-
cing in 10 patients affected by RASopathies.
Our experience with the proband and his father,
taken together with the known broad intrafamilial va-
riability of the phenotype in RASopathies, is a reminder of
how clinical examinations of parents and other first-
degree relatives (although referred to as healthy) can
be useful in designing suitable diagnostic approaches
to children with suspected NF1/NS/LS/NFLS. In our
case report, the clinical evaluation of the father would
have helped to orientate the stratified molecular diag-
noses, priorizing PTPN11 analysis. The clinical exam-
ination of both parents should be considered in thegenetic counselling of couples subjected to the in vitro
fertilization.
Finally, to our knowledge, this is the third report of the
occurrence of Arnold Chiari malformation [24,25] and the
second one of syringomyelia with LS [24]. Instead NS is
already known to have a high incidence of spinal cord
malformations [26] and there are some evidences that this
is also true for NF1 [27]. This confirms that LS and NS
belong to a clinical spectrum together with NFNS [28].
Conclusions
In summary, our observations and those described in
previously published reports support the indication of
molecular testing of NF1 and other RASopathies genes in
cases in which the diagnosis of RASopathy is uncertain or
in which the phenotype is borderline. Genome sequencing
might represent the right approach for screening RASo-
pathies. This would allow physicians to conduct proper
follow-up and genetic counseling, thus reducing the
medical and economic costs associated with incorrect
diagnoses of RASopathies.
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